Beyond Air (NASDAQ:XAIR) Announces Quarterly Earnings Results, Misses Estimates By $0.31 EPS

Beyond Air (NASDAQ:XAIR) posted its quarterly earnings data on Friday. The company reported ($0.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.54) by ($0.31), Zacks reports. The firm had revenue of $2.19 million for the quarter, compared to analyst estimates of $2.15 million. Beyond Air had a negative return on equity of 261.08% and a negative net margin of 632.51%.

Here are the key takeaways from Beyond Air’s conference call:

• Revenue grew 105% year‑over‑year to $2.2M, with an installed base of more than 45 hospitals, customer retention above 90%, and over half of customers on multi‑year agreements, indicating early commercial traction.
• Commercial momentum includes national GPO agreements with Premier and Vizient, the first sale into a VA Medical Center, expansion of distribution to 40 countries, and repeat international accessory orders, supporting broader adoption.
• Management expects FDA clearance for the Gen 2 LungFit PH system by the end of calendar 2026 and says Gen 2’s smaller size, transport compatibility, simplified operation, and extended service intervals should expand the addressable market.
• Timing risk remains for Gen 2 because launch is contingent on a contract manufacturer inspection and continued engagement with the FDA, which could delay approval or commercialization.
• Operating expenses fell ~36% YoY to about $6.9M, net loss narrowed to $7.3M, cash and equivalents were $17.8M at quarter end, and subsequent financings give management confidence in a runway into calendar 2027, albeit conditional on meeting revenue and cost targets.

Beyond Air Stock Performance

NASDAQ XAIR traded up $0.06 on Friday, hitting $1.08. 448,222 shares of the stock were exchanged, compared to its average volume of 15,107,503. The company has a debt-to-equity ratio of 0.77, a current ratio of 4.24 and a quick ratio of 3.73. The business’s fifty day moving average is $1.14 and its 200 day moving average is $1.83. Beyond Air has a 52 week low of $0.67 and a 52 week high of $8.01. The company has a market capitalization of $8.62 million, a PE ratio of -0.14 and a beta of 0.39.

Institutional Investors Weigh In On Beyond Air

A number of institutional investors and hedge funds have recently modified their holdings of the company. Geode Capital Management LLC lifted its stake in Beyond Air by 57.5% in the 4th quarter. Geode Capital Management LLC now owns 67,678 shares of the company’s stock valued at $49,000 after purchasing an additional 24,695 shares during the last quarter. Alyeska Investment Group L.P. bought a new stake in Beyond Air in the third quarter valued at approximately $1,753,000. Virtu Financial LLC bought a new stake in Beyond Air in the third quarter valued at approximately $48,000. Finally, Osaic Holdings Inc. lifted its position in shares of Beyond Air by 26.4% in the second quarter. Osaic Holdings Inc. now owns 162,560 shares of the company’s stock valued at $29,000 after buying an additional 34,000 shares during the last quarter. 31.50% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the company. Weiss Ratings reissued a “sell (e)” rating on shares of Beyond Air in a research note on Monday, December 22nd. Rodman & Renshaw began coverage on shares of Beyond Air in a research report on Tuesday, January 20th. They issued a “buy” rating on the stock. Finally, D. Boral Capital reissued a “buy” rating and set a $11.00 price objective on shares of Beyond Air in a research note on Wednesday, January 21st. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Beyond Air presently has a consensus rating of “Hold” and a consensus target price of $11.00.

Beyond Air Company Profile

Beyond Air, Inc is a clinical-stage medical technology company focused on the development and commercialization of inhaled nitric oxide (NO) therapy for pulmonary and respiratory diseases. The company’s proprietary LungFit® platform delivers pulsed, low-dose nitric oxide gas through compact, portable devices designed to support treatments in both inpatient and outpatient settings. Beyond Air’s approach leverages NO’s antimicrobial, vasodilatory and anti-inflammatory properties to address a range of unmet needs in respiratory medicine.

The company’s lead candidate, LungFit® PH, is under investigation for the treatment of pulmonary hypertension, with ongoing clinical studies assessing its impact on pulmonary arterial pressure and exercise capacity.